Emcure FY26 Revenue Crosses ₹9,204 Cr, PAT Up 33%

Emcure Pharmaceuticals reported audited standalone and consolidated financial results for Q4 and FY26 ended March 31, 2026, approved by the Board on May 5, 2026.
Consolidated revenue reached ₹9,204.40 crore for FY26, a 16.6% YoY increase, with net profit at ₹941.27 crore, up 33.1% YoY.
The Board recommended a final dividend of ₹3.60 per share and disclosed acquisitions including Zuventus minority buyout and Cutimed Inc. in Canada.
Exceptional items included ₹260.57 million for labour code provisions and ₹428.64 million for Mantra Pharma contingent consideration true-up.